Bourgeon Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 100.7% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 723,974 shares of the company's stock after acquiring an additional 363,252 shares during the period. Teva Pharmaceutical Industries makes up approximately 2.4% of Bourgeon Capital Management LLC's investment portfolio, making the stock its 15th largest position. Bourgeon Capital Management LLC owned about 0.06% of Teva Pharmaceutical Industries worth $12,134,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the company. Ion Asset Management Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 6.5% during the first quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company's stock worth $599,945,000 after acquiring an additional 2,383,500 shares during the period. Menora Mivtachim Holdings LTD. boosted its holdings in shares of Teva Pharmaceutical Industries by 2.8% during the first quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company's stock worth $448,640,000 after acquiring an additional 808,074 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 1.2% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock worth $404,775,000 after acquiring an additional 300,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 197,885.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock valued at $338,989,000 after buying an additional 22,044,407 shares during the period. Finally, Duquesne Family Office LLC boosted its stake in shares of Teva Pharmaceutical Industries by 65.4% in the first quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock valued at $228,702,000 after buying an additional 5,882,350 shares during the period. Institutional investors own 54.05% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. UBS Group boosted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. Finally, The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a "buy" rating and a $24.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $25.14.
View Our Latest Analysis on TEVA
Teva Pharmaceutical Industries Trading Up 4.5%
Shares of TEVA stock opened at $19.17 on Tuesday. The stock's fifty day moving average price is $17.83 and its two-hundred day moving average price is $16.72. The company has a market cap of $21.99 billion, a PE ratio of -119.81, a P/E/G ratio of 1.07 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company's revenue was up .3% compared to the same quarter last year. During the same quarter last year, the business posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Placid Jover sold 6,053 shares of the company's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider owned 6,774 shares of the company's stock, valued at $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company's stock.
About Teva Pharmaceutical Industries
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
